Additional data analysis offers greater insight into phase 2 findings of Bionomics PTSD drug

Additional data analysis offers greater insight into phase 2 findings of Bionomics’ PTSD drug

03:36 EST 19 Feb 2019 | Pharmaceutical Business Review

Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at

More From BioPortfolio on "Additional data analysis offers greater insight into phase 2 findings of Bionomics’ PTSD drug"